Correction to: Genetics in Medicine 2020; https://doi.org/10.1038/s41436-020-0814-5, published online 13 May 2020
The original version of this Article omitted an essential reference (“Meulemans L, Mesman RLS, Caputo SM, et al. Skipping nonsense to maintain function: the paradigm of BRCA2 exon 12. Cancer Res. 2020;80(7):1374–1386. DOI: 10.1158/0008-5472.CAN-19-2491”). This has now been added in both the PDF and HTML versions of the Article.
In addition, the original version of this Article contained a typo in the sentence “However, two variants in respectively the splice acceptor site (c.517–2A>G) and donor site (c.631+2T>G) of exon 7 were classified as pathogenic based...” that was incorrectly given as “However, two variants in respectively the splice donor site (c.517–2A>G) and acceptor site (c.631+2T>G) of exon 7 were classified as pathogenic based...”. Where “donor” should be “acceptor” and vice versa. This has now been corrected in both the PDF and HTML versions of the Article.
Finally, the original version of this Article contained an incorrect supplementary file. This has now been replaced in the HTML version of the Article.
About this article
Cite this article
Mesman, R.L.S., Calléja, F.M.G.R., de la Hoya, M. et al. Correction: Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2. Genet Med 22, 1427–1428 (2020). https://doi.org/10.1038/s41436-020-0883-5